
    
      This study is a multi-centre, observational, prospective study to be conducted at 60
      hospitals across IndiaThe study will be initiated after obtaining written approval of
      Independent Ethics Committee (IEC) and written Informed consent of the patient.

      Patients who had been hospitalized for ACS and are on ticagrelor on discharge or on
      Ticagrelor therapy for â‰¤ 1month will be enrolled in the study and followed up for a period of
      12 months. During the follow-up period of up to 12 months (according to the label),
      assessment visits will follow the routine clinical practice. No visits or measurements will
      be made mandatory by the protocol
    
  